B + L options license for compound to treat DES

Article

 

Montreal, Canada and Madison, NJ-Bausch + Lomb has acquired an option to license MIM-D3 and developed by Mimetogen Pharmaceuticals Inc. an investigational compound currently in Phase II development for the treatment of dry eye syndrome (DES).

MIM-D3 has the potential to be the first in a new class of agents called TrkA agonists, according to Mimetogen. MIM-D3 stimulates the production of mucin, vital for the protection and overall health of the ocular surface. In addition, MIM-D3 may have additional benefits than currently available dry eye therapies including the potential to improve neural function, which may improve corneal sensitivity and integrity.

Phase II study results for MIM-D3 demonstrated that the use of MIM-D3, dosed bid, results in consistent improvements across multiple dry eye signs and symptoms with no safety or tolerability issues. A Phase III study is scheduled to begin before the end of 2013, which will be conducted by Ora Inc.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD, and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.
Dr Ashley Tucker Wallace discusses the intersection of pediatric dry eye and myopia control
© 2025 MJH Life Sciences

All rights reserved.